Identification and Characterization of Ovarian Carcinoma Peptide Epitopes Recognized by Cylotoxic T Lymphocytes
Annual rept. 1 Nov 2004-31 Oct 2005
VIRGINIA UNIV CHARLOTTESVILLE
Pagination or Media Count:
The purpose of the research is to identify new ovarian cancer tumor antigens that can be used in the immunotherapeutic treatment of ovarian cancer. The scope of this work involves 1 identifying the peptide antigens recognized by ovarian reactive cytotoxic T lymphocytes CTL by using an antigen-unbiased, mass spectrometric approach to antigen identification and 2 identify peptide antigens within the Her-2neu, folate binding protein FBP, and TAG proteins that give rise to ovarian reactive CTL. Two TAG-derived peptides, SLGWLFLLL which is recognized in association with HLA-A2, and LSRLSNRLL which is recognized in association with HLA-B8, have tentatively been identified as novel antigens. These antigens should be useful in the treatment of ovarian cancer patients with TAG tumor cells. Ten established ovarian cancer cell lines and 29 ovarian cancer patient archival samples have been characterized for expression of class I MHC molecules, Her-2neu, FBP, and TAG. These characterized materials will be used to generate additional ovarian cancer cell lines and ovarian cancer reactive CTL lines that will be used for the mass spectrometric identification of additional tumor antigens, and they will be used for the specific identification of Her-2neu, FBP, and TAG derived antigens. The overall significance of this work is that the newly discovered antigens can be incorporated into a therapeutic vaccine for the treatment of ovarian cancer.
- Anatomy and Physiology